Founded in 2019, PTM Therapeutics is a San Francisco-based, pre-clinical stage startup that strives to “develop therapeutics for the betterment of human health span and well-being.” They achieve this by harnessing antibody technology against post-translational modification (PTM) targets for gastrointestinal (GI) and oncology diseases. The company collaborates with the University of Michigan and Emory University to exclusively license these therapies to target conditions like inflammatory bowel disease (IBD). The company’s research revolves around the theory that PTMs are implicated in disease states. PTMs are chemical alterations made to proteins after they are synthesized in cells. These changes impact a protein’s structure, stability, and activity, ultimately affecting cellular processes like signaling or gene expression. PTMs are crucial for cellular functionality, allowing proteins to adopt diverse
